MicroRNA profiles as predictive markers of response to azacitidine therapy in myelodysplastic syndromes and acute myeloid leukemia

Autor:	Monika Belickova, Anna Jonasova, Zdenek Krejcik, Jaroslav Cermak, Jan E. Dyr, Andrea Hrustincova, Michaela Dostalova Merkerova, Hana Votavova
Rok vydání:	2018
Předmět:	Male 0301 basic medicine Oncology Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Azacitidine CD34 03 medical and health sciences 0302 clinical medicine Downregulation and upregulation Internal medicine microRNA Genetics medicine Humans Aged business.industry Myelodysplastic syndromes Myeloid leukemia General Medicine medicine.disease Leukemia Myeloid Acute MicroRNAs 030104 developmental biology medicine.anatomical_structure Myelodysplastic Syndromes 030220 oncology & carcinogenesis Female Bone marrow business Nucleoside medicine.drug
Zdroj:	Cancer Biomarkers. 22:101-110
ISSN:	1875-8592 1574-0153
Popis:	Background Azacitidine (AZA) is a nucleoside analog used for treatment of myelodysplasia and the prediction of AZA responsiveness is important for the therapy management. Methods Using microarrays and reverse-transcription quantitative-PCR, we analyzed microRNA (miRNA) expression in bone marrow CD34+ cells of 27 patients with higher-risk myelodysplastic syndromes or acute myeloid leukemia with myelodysplasia-related changes before and during AZA treatment. Results At baseline, we found that future overall response rate was significantly higher in patients with upregulated miR-17-3p and downregulated miR-100-5p and miR-133b. Importantly, the high level of miR-100-5p at baseline was associated with shorter overall survival (HR = 4.066, P= 0.008). After AZA treatment, we observed deregulation of 30 miRNAs in responders (including downregulation of miR-10b-5p, miR-15a-5p/b-5p, miR-24-3p, and miR-148b-3p), while their levels remained unchanged in non-responders. Conclusions Our study demonstrates that responders and non-responders have distinct miRNA patterns and that the level of specific miRNAs before therapy may predict the efficacy of AZA treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bafe41bd87a8afaa3380df8d35739aa https://doi.org/10.3233/cbm-171029 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.